Acute renal toxicity and its detection by the Yellow card reporting scheme

K. Davidson, S. Kerr, Moira Kinnear, D.N. Bateman

Research output: Contribution to journalConference Contribution


Paper presented at the United Kingdom Clinical Pharmacy Association (UKCPA) autumn symposium, Hinckley, 18-20 Nov 2011 (Oral Communication OC 4).
The aim of this study was to describe frequency and profile of reporters of yellow card (YC) reports for renal toxicities in Scotland and the UK, and to identify which drugs are reported and at what frequency and to identify risk factors for drug induced renal toxicity.
Data were obtained through a retrospective analysis of the UK YC database from 2002 to 2006 using specified renal urinary Medical Dictionary of Regulatory Activities (MedDRA) terms to identify relevant yellow card reports. In the UK, 1484 (2.2%) yellow cards were received by the MHRA for the specified MedDRA terms compared to 152 (2.4%) for Scotland. In each case, the top three drug classes implicated were NSAIDs, drugs affecting the renin-angiotensin system and lipid-lowering agents. Comparison of reporting by different healthcare professionals showed a comparable split between GPs, hospital doctors and hospital pharmacists.
Original languageEnglish
Pages (from-to)S11-S12
Number of pages2
JournalClinical Pharmacist
Issue numberApril (Supplement 2)
Publication statusPublished - Apr 2012
EventUnited Kingdom Clinical Pharmacy Association autumn symposium 2011 - Hinckley, United Kingdom
Duration: 18 Nov 201120 Nov 2011


  • adverse effects
  • united kingdom
  • scotland
  • kidney
  • adverse reaction reporting
  • acute
  • renal toxicity
  • detection
  • yellow card
  • reporting
  • scheme


Dive into the research topics of 'Acute renal toxicity and its detection by the Yellow card reporting scheme'. Together they form a unique fingerprint.

Cite this